Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650887 | 0.97 | THRB (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL145252 | 0.94 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL200022 | 0.94 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL201000 | 0.94 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL28984423 | 0.92 | ALDH1A1 (0.38) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL201684 | 0.89 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL198421 | 0.89 | ALDH1A1 (0.39) | ALDH1A1THRBMEN1HTTKMT2A | |
| SCHEMBL150256 | 0.88 | — | — | |
| SCHEMBL5047150 | 0.88 | ALDH1A1 (0.43) | ALDH1A1THRBTSHR | |
| SCHEMBL5519 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978427-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR INT AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2978427-A1 | FE(III) COMPLEXES FOR TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | Vifor (International) AG (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-9248134-B1 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-02-02 | — | — | US | disclosed |
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-01-21 | — | — | US | disclosed |
| WO-2014154797-A1 | FE(III) COMPLEXES FOR TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANAEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| EP-1120399-B1 | Naphthalene compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2004-06-09 | — | — | EP | disclosed |
| EP-1120400-B1 | Naphtahlene compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2003-09-24 | — | — | EP | disclosed |
| EP-0962445-B1 | Acetylene compound, liquid crystal composition and liquid crystal element | MITSUI CHEMICALS INC (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-0757032-B1 | Naphthalene compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-12-12 | — | — | EP | disclosed |
| EP-0751133-B1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1120399-A1 | Naphthalene compound, and liquid crystal composition and liquid crystal element using the same | Mitsui Chemicals, Inc. (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120400-A1 | Naphtahlene compound, and liquid crystal composition and liquid crystal element using the same | Mitsui Chemicals, Inc. (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-6217793-B1 | Acetylene compound, liquid crystal composition and liquid crystal element | MITSUI CHEMICALS, INC. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-0962445-A1 | Acetylene compound, liquid crystal composition and liquid crystal element | Mitsui Chemicals, Inc. (JP) | 1999-12-08 | — | — | EP | disclosed |
| US-5861108-A | IMPROVES HIGH SPEED RESPONSE PROPERTY AND TEMPERATURE DEPENDENCY OF THE RESPONSE TIME | MITSUI CHEMICALS, INC. (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0757032-A2 | Naphthalene compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
| EP-0189774-B1 | PROCESS FOR PRODUCTION OF N,N-DISUBSTITUTED CARBOXYLIC ACID AMIDES | TOKUYAMA SODA KABUSHIKI KAISHA (JP) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015716-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | ALDH1A1 1539/4885THRB 2329/4885MEN1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.